Abstract #1841

Fluorine-19 MR Characterisation of Siponimod as MR Theranostic Approach in the Treatment of Multiple Sclerosis

Christian Prinz¹, Fatima Sherazi¹, Ludger Starke¹, Paula Ramos Delgado¹, Andre Kuehne², Thoralf Niendorf^1,2,3, and Sonia Waiczies¹

¹Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, ²MRI TOOLS GmbH, Berlin, Germany, ³Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

Siponimod is a trifluorinated anti-inflammatory drug indicated for Multiple Sclerosis that could be potentially tracked in pharmacokinetic studies by fluorine-19 (¹⁹F) MR techniques in order to support therapeutic monitoring. In this study, we investigated the ¹⁹F MR properties of siponimod and its dependency on environmental factors. We found a temperature dependence of the relaxation times T₁ and T₂ and identified a T₂-drop in the presence of human serum. We identified UTE as SNR-efficient MR pulse sequence to study siponimod physiologically and show the potential of tailoring MR methods in the future to individual patient therapeutic needs.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.